CD38 and acute myeloid leukemia: The results are compatible with the following model: what the paper shows is that in CD34 positive AML cases, it is the percentage of the CD34+CD38- population at diagnosis that strongly correlates with clinical outcome and not the percentage of CD34+CD38+ or CD34- cells.